News | September 03, 2009

PreSCD II Registry Shows ICDs Caused 44 Percent Reduction in Mortality for MI Survivors

September 3, 2009 – Boston Scientific Corp. said Tuesday long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II) found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality when implanted in patients following myocardial infarction.

The mortality reduction trend was also observed in high-risk patients with severely reduced heart function. Analysis of the data was presented by professor Heinz Völler, M.D., Klinikum am See, Ruedersdorf, Germany, at the annual European Society of Cardiology (ESC) Congress in Barcelona.

Heart attack survivors have an increased risk for sudden cardiac death, and patients with impaired left ventricular function in particular benefit from protection by an ICD. Major clinical trials such as MADIT II suggest ejection fraction should be used to characterize risk and determine which patients should receive an ICD. Data from PreSCD II revealed that within the highest risk subgroup (ejection fraction of less than or equal to 30 percent), only 22 percent of patients were prescribed ICD therapy.

"The PreSCD II data provide real-world confirmation of the findings of randomized clinical trials that have shown ICDs reduce mortality following a heart attack," said Dr. Völler. "In addition, PreSCD II confirms that actual ICD implantation rates for the highest risk subgroup were lower than those recommended by current guidelines and other study results. This is a significant concern because the mortality reduction associated with an ICD was greatest among these patients. We were also interested to observe a survival benefit that increased with the time interval between heart attack and ICD implantation."

The PreSCD II registry enrolled 10,612 heart attack survivors between 2002 and 2005 in 19 centers in Germany.

For more information: www.bostonscientific.com

Related Content

Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init